GoKawiilFDA Clears PrecivityAD2 Blood Test for Alzheimer's in Adults as Young as 40
The FDA has approved PrecivityAD2, a blood test that detects amyloid and tau biomarkers linked to Alzheimer's disease in symptomatic patients starting at age 40. In a validation study of 1,142 adults, the test correctly identified positive biomarkers 97.6% of the time, even among patients with conditions like kidney disease or diabetes that can otherwise skew results.
GoKawiil's interpretation of the reporting above, not reported fact.
This marks the third FDA-cleared Alzheimer's blood test in just over a year, signaling a rapid shift away from costly, invasive diagnostics like PET scans and spinal taps toward simpler blood draws. Earlier, more reliable detection could help doctors intervene sooner, improve clinical trial design, and pave the way for targeted treatments—though the test is meant for symptomatic patients, not as a general screening tool.
- PrecivityAD2 uses mass spectrometry to measure amyloid and tau protein biomarkers from a single blood sample.
- The test showed 97.6% accuracy in identifying positive biomarkers, even in patients with comorbidities.
- It's intended for symptomatic adults 40 and older, not as a routine screening test for healthy individuals.
The 36-Hour Day (Johns Hopkins Press) — As blood tests make earlier Alzheimer's detection possible, families are getting answers sooner than ever, and this classic guide is the go-to companion for what comes next. It walks caregivers through daily routines, communication, and planning for dementia care in plain, compassionate language.
See The 36-Hour Day (Johns Hopkins Press) on Amazon → Affiliate link — we may earn a commission on purchases, at no extra cost to you. Product picked by AI based on this article; it is not a tested recommendation.Source: science.slashdot.org, 2026-08-24
Published there as: “FDA Approves First Alzheimer's Blood Test For Americans As Young As 40”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.